Sentences with phrase «myeloid diseases»

These results demonstrate that the JAK2V617F mutation contributes to the pathogenesis of a spectrum of myeloid diseases including MPD and AML but not to ALL.

Additional in vitro and in vivo studies are needed to determine the cause of the specificity of JAK2V617F for myeloid diseases, as second mutations, host modifiers, differential cytokine receptor expression, and other factors may influence the ultimate phenotype of hematopoietic progenitors that acquire the JAK2V617F mutation.

The identification of a single disease allele in 3 related myeloid diseases suggests that the JAK2V617F mutation may be important in the pathogenesis of additional hematopoietic malignancies.

In a 2015 Nature Communications paper, Rao, who heads LJI's Division of Signaling and Gene Expression, reported that TET2 / 3 mutations caused myeloid disease resembling acute myeloid leukemia in mice.

Not exact matches

Researchers at University of California San Diego School of Medicine and Moores Cancer Center have identified RNA - based biomarkers that distinguish between normal, aging hematopoietic stem cells and leukemia stem cells associated with secondary acute myeloid leukemia (sAML), a particularly problematic disease that typically afflicts older patients who have often already experienced a bout with cancer.

PHILADELPHIA --(July 11, 2017)-- Researchers at The Wistar Institute, an international leader in biomedical research in the fields of cancer, immunology and infectious diseases, with collaborators at Indiana University Melvin and Bren Simon Cancer Center and Syndax Pharmaceuticals, Inc., (Nasdaq: SNDX) announce the results of a preclinical study demonstrating that entinostat, Syndax's oral, Class - I histone deacetylase inhibitor, enhances the antitumor effect of PD - 1 (programmed death receptor - 1) blockade through the inhibition of myeloid derived suppressor cells (MDSCs).

Based on empirical data obtained in cases of chronic myeloid leukemia, a myeloproliferative syndrome controlled by the immune system, and in solid tumors, we observe both the possible contribution of innate CD8 (+) T cells to cancer disease control and their susceptibility to tumor immune subversion.

He uses the paradigm of nuclear hormone receptor activation / signaling and the contribution of this process to myeloid cell differentiation, function, and to diseases, involving these cells, such as atherosclerosis, tissue regeneration, metabolic, and various inflammatory disorders, as his model systems.

Removal of a fifth course of chemotherapy containing cytarabine resulted in worse overall survival and disease - free survival in pediatric patients with low - risk acute myeloid leukemia (AML), according to the results (abstract 10515) of a pooled analysis of two Children's Oncology Group (COG) trials presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2 — 6 in Chicago.

Anna Huttenlocher, University of Wisconsin, USA Neutrophils in the Tumor Microenvironment Neutrophils, Wounds, and Cancer Progression Stefan Kaufmann, Max Planck Institute, Germany Pathology and immune reactivity: understanding multidimensionality in pulmonary tuberculosis Constitutive BAK activation as a determinant of drug sensitivity in malignant lymphohematopoietic cells Kathryn Moore, New York University, USA MicroRNA -33-dependent regulation of macrophage metabolism directs immune cell polarization in atherosclerosis Lalita Ramakrishnan, University of Cambridge, UK Myeloid Growth Factors Promote Resistance to Mycobacterial Infection by Curtailing Granuloma Necrosis through Macrophage Replenishment Beth Stevens, Harvard University, USA Microglia: Dynamic Mediators of Synapse Development and Plasticity Do glia drive synaptic and cognitive impairment in disease?

Allogeneic Sibling Donor Peripheral Blood Stem Cells Transplantation With Myeloablative Conditioning for Chronic Myeloid Leukemia in Blast Crisis - Successful Treatment Despite Severe Phase of the Disease

In 2001 imatinib was approved for the treatment of chronic myeloid leukemia, a disease that is almost universally caused by a single genetic mutation, known as the Philadelphia chromosome, and its resulting mutant protein.

This video reviews the biology of secondary acute myeloid leukemia and highlights some of the latest findings in the treatment of this disease.

Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) exist along a continuous disease spectrum starting with early - stage MDS, which may progress to advanced MDS, AML, cured AML or resistant AML.

Low - dose donor CD8 + cells in the CD4 - depleted graft prevent allogeneic marrow graft rejection and severe graft - versus - host disease for chronic myeloid leukemia patients in first chronic phase.

The CIRM board also announced the approval of US $ 58.8 million in funding for five new clinical trials which will study potential treatments for a variety of diseases and conditions, namely malignant glioma, acute myeloid leukemic, neutropenia, high - risk type 1 diabetes and kidney disease.

Its work is focused ostensibly on breast, colon and lung cancers, as well as leukemia and a separate blood disease — myeloid dysplastic syndrome.

These mutant kinases are attractive therapeutic targets, as demonstrated by the efficacy of imatinib in BCR - ABL — positive chronic myelogenous leukemia (CML), 5 as well as in MPD associated with activating alleles involving PDGFRA or PDGFRB.2, 6,7 In addition, activating mutations in the FLT3 receptor tyrosine kinase are the most common genetic event in acute myeloid leukemia (AML), and specific inhibitors of the FMS - like tyrosine kinase 3 (FLT3) have entered late - stage clinical trials.8 Although mutations in tyrosine kinases and in other genes have been identified in a subset of MPD and AML, in many cases the genetic events that contribute to the molecular pathogenesis of these diseases remain unknown.

New study uses CRISPR technology to link a YEATS domain protein (ENL) to Leukemia (3/1/17) Associate Professor Xiaobing Shi, Assistant Professor Hong Wen and collaborators David Allis and Scott Armstrong have shown that ENL, a YEATS domain containing protein that recognizes histone acetylation, is required for disease maintenance in acute myeloid leukemia (AML)(Wan L et al, Nature, 2017).

Hypoxia Inducible Factor - 1α in Astrocytes and / or Myeloid Cells Is Not Required for the Development of Autoimmune Demyelinating Disease

This group includes patients with advanced myeloproliferative neoplasms (accelerated phase, blast phase, or post — myeloproliferative neoplasm acute myeloid leukemia) characterized by poor outcomes and aggressive disease.

«Monocytes and macrophages have a way to amplify inflammation in the central nervous system,» says Shaked, «which really shows that myeloid cells play an unexpected and important role in diseases of the brain.»

Smoking Worsens Prognosis for Patients With CML: The results of the German CML Study IV report a link between mortality and disease progression in patients with chronic myeloid leukemia (CML) who are smokers.

Genomic BCR - ABL1 breakpoint characterization by a multi-strategy approach for personalized monitoring of residual disease in chronic myeloid leukemia patients

Acute myeloid leukemia (AML) is the leading cause of leukemia mortality in the United States.1 Curative treatment involves intensive induction chemotherapy, before proceeding to either consolidation chemotherapy or allogeneic stem cell transplantation based on the patient's risk for relapse.2 This approach has been employed for > 4 decades and, although most individuals achieve complete remissions with front - line therapy, 3 the majority of patients ultimately relapse with drug - resistant disease, and overall survival rates remain disappointingly poor.4 The limited ability of many patients to tolerate the intense chemotherapy - based treatments, in particular hematological toxicity, further contributes to the poor outcomes noted in this disease.

The project «Preprogrammed versus stochastic clonal evolution of relapsing Acute Myeloid Leukaemia: Impact on disease development and therapeutic responses» will dissect why the subpopulations of primary human blood cancer cells that drive leukaemic relapse resist relevant clinical treatments in vivo.

About Blog An Acute Myeloid Leukemia (AML) patient's observations about life, death, and the odds of beating a disease with a five year survival rate of 26 percent.